Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase II single-arm study designed to evaluate the efficacy and safety of Sac-TMT + KL-A167 in 35 patients with PD-L1+, HR+/HER2- metastatic breast cancer who previously treated with CDK4/6 inhibitor. The primary endpoint is the 6-month PFS rate. Treatment will continue until disease progression or intolerable toxicity, with periodic imaging assessments and survival follow-up.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Rak piersi HR+/HER2- (receptory hormonalne dodatnie, receptor HER2 ujemny)
- •Zaawansowana, nawracająca lub przerzutowa postać raka piersi
- •Progresja choroby podczas lub w ciągu 12 miesięcy po leczeniu inhibitorem CDK4/6
- •Dodatni wynik testu na PD-L1
- •Co najmniej jeden zmierzalny guz
- •Dobry stan ogólny (ECOG 0 lub 1) i spodziewana długość życia powyżej 12 tygodni
- •Prawidłowe funkcje narządów wewnętrznych (wątroba, nerki, serce, krew)
✗ Disqualifies
- •Chemioterapia przeprowadzona w stadium zaawansowanym
- •Terapia zorientowana na topoisomerazę I lub immunoterapia przeprowadzona w stadium zaawansowanym
- •Nawrót lub przerzuty w ciągu 12 miesięcy po ostatniej chemioterapii wczesnego stadium
- •Przerzuty do mózgu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- May 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, China
Trial contact
Fei Xu, MD
Kuikui Jiang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.